Be Biopharma has raised $92 million to support the first-in-human Phase 1/2 trial of BE-101, which is made to lower bleeding ...

Columnist Jennifer Lynne interviews Debbie Murray, a New Yorker whose hemophilia B diagnosis didn't occur until she was almost 51.

Two hemophilia patients in the U.S. who struggled for years with bleeds have been given Hemgenix, the first gene therapy ...

Now that his adult sons are managing their own hemophilia care, columnist Joe MacDonald is able to consider moving for a job.

Columnist G Shellye Horowitz wasn't surprised to learn she had osteopenia, as her bleeding disorder increases her risk of low ...

Sangamo will regain full rights to giroctocogene fitelparvovec, a gene therapy candidate for hemophilia A, after Pfizer ended ...

When I tell people I’m a woman with hemophilia, I’m often met with the same response: “Well, that is really unusual. It’s rare for women to have hemophilia!” This ubiquitous misconception is the bane ...

Observing her husband, columnist Alliah Czarielle sees that getting older is a great equalizer, as more in their community have health woes.

MacDonald worries about her adult son being complacent when it comes to administering his hemophilia medication.

Prophylactic, or preventive, treatment with factor VIII (FVIII) replacement therapy for four years reduced annual bleeding rates by 91% for people with severe hemophilia A, a study from Taiwan ...